Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
NCT ID: NCT07169825
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
25 participants
INTERVENTIONAL
2026-02-13
2028-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT07096999
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
NCT06828263
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
NCT07054346
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT04430192
Radioligand fOr locAl raDiorecurrent proStaTe cancER
NCT05230251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• To determine the personalized radiation dose to tumors and critical organs of participants with compromised renal and / or bone marrow function.
Secondary Objectives
* To compare target radiation doses based on varying SPECT scan duration. Plot the variability in target radiation dose versus scan duration.
* To compare the image quality and dosimetry results when considering the low, high, and both energy peaks of Lu-177.
* To compare target radiation doses based on multiple imaging time points versus a single time point and identify which time point is most suited for this evaluation.
* To compare target radiation doses derived from organ versus voxel dosimetry calculation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA
Lu-177
Given by IV
SPECT
SPECT/CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lu-177
Given by IV
SPECT
SPECT/CT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Participants who do not wish to be imaged multiple times as per the study protocol.
* Women and children since this is treatment for prostate cancer.
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GE Healthcare
INDUSTRY
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guofan Xu, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-06603
Identifier Type: OTHER
Identifier Source: secondary_id
2024-1702
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.